Trump thanks Regeneron and others for signing MFN agreement

Summary

President Trump thanked Regeneron Pharmaceuticals for signing a ‘Most Favored Nation’ (MFN) agreement, where the company commits to providing prescription drugs at the lowest international prices Zhitong. This deal is part of a broader policy where pharmaceutical companies can avoid new import tariffs by reshoring production to the U.S. and signing pricing agreements with the Department of Health and Human Services .

Impact Analysis

So Regeneron is the first big domino to fall in Trump’s drug-pricing crusade. By signing this Most Favored Nation (MFN) deal, they’re essentially capping their U.S. prices at the lowest levels they offer globally to dodge those aggressive new tariffs . It’s a classic ‘protection money’ play: reshore production and lower prices, or get taxed into oblivion .

This signals that the administration’s ‘de-China’ supply chain pivot is moving from rhetoric to reality. For Regeneron, it’s a calculated margin hit in exchange for regulatory ‘safe harbor’ until 2029 . But the real losers here are the foreign innovators—especially Chinese biotechs—who can’t pivot their entire manufacturing base overnight . They’re looking at a 20% tariff wall. Bottom line: the era of high-margin U.S. pricing acting as a global subsidy is under fire. We should look at domestic reshoring winners but stay wary of the immediate P&L impact from these MFN price caps across the sector.